Syntara Limited · ASX:SNT
Syntara — Canaccord Drug & Device Conference 2026
20 slides from Syntara's conference presentation, Oct 13, 2026
Slide 1: Canaccord Drug & Device Conference
rsonal use only Canaccord Drug & Device Conference Gary Phillips, CEO October 13th 2026
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT rsonal use only This document contains risks, uncertainties and other forward-looking statements, factors, many of which are including statements beyond our control, and which concerning Syntara’s future may cause actual results to financial position, plans, and the differ
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS rsonal use only Australian-founded Backed by Multiple shots on Funded into FY28 with near clinical stage specialist healthcare goal from additional term data to drive value drug developer investors – Phase 2, Phase 1 and over the next 44% institutional preclinical assets 12-18
Slide 4: Shareholders & Cash
SHAREHOLDERS & CASH Financial Information (ASX: SNT) Share Price & Volume - YTD Share price – 9th October 2026 $0.025 Close rsonal use only 0.04 Market cap A$49.1m Cash balance (30 Jun 2026 proforma1) A$18.2m 0.03 Enterprise value A$30.9m 0.02 0.01 Institutional Ownership 30 Jun 26 0 D&A Income Limi
Slide 5: Three Assets Create Multiple Paths to Value
THREE ASSETS CREATE MULTIPLE PATHS TO VALUE A diversified clinical-stage pipeline across blood cancers, fibrosis and neurodegenerative disease ASSET INDICATION TOTAL ADDRESSABLE MARKET DEVELOPMENT STATUS rsonal use only • Phase 2a clinical proof of concept in MF - complete Haematological Myelofibros
Slide 6: Amsulostat: Lead Asset and a Key Driver of Value
• FDA IND and orphan drug designation in rsonal use only myelofibrosis • First and best in class pan-LOX inhibitor • Long patent life AMSULOSTAT: • Multiple Nature publications LEAD ASSET AND A KEY • Final Phase 2a trial data in combination with DRIVER OF VALUE ruxolitinib presented at ASH 2025 • Cl
Slide 7: Myelofibrosis
MYELOFIBROSIS A rare type of bone marrow cancer that disrupts the body’s normal production of blood cells KEY FACTS Myelofibrosis characterised by a build up of scar tissue • Orphan disease affects ~55k people in 7MM (fibrosis) in bone marrow and abnormal proliferation of (USA, Japan, 5EU); USA ~ 20
Slide 8: Myelofibrosis: Limited Treatment Options Currently
MYELOFIBROSIS Limited treatment options currently Current standard of care (SoC): JAK inhibitors Amsulostat rsonal use only In contrast to SoC, amsulostat intervenes at the Key• Class Factsof drugs used in the management of splenomegaly source, inhibiting the family of lysyl oxidase (enlarged spleen
Slide 9: Amsulostat Shows Competitive Efficacy
AMSULOSTAT SHOWS COMPETITIVE EFFICACY Comparison of open-label Phase 2 studies in suboptimal patient populations Phase 2 Open Label Trial Results in Suboptimal Patient Population Latest Program Drug Status Baseline Characteristics rsonal use only N TSS50 SVR25 SVR35 (median, range) Second P3 naïve M
Slide 10: Strong Interest in MF Assets from Strategics
STRONG INTEREST IN MF ASSETS FROM STRATEGICS Target / Acquiror / / / / / rsonal use only DATE OF JULY-2026 APRIL-2026 MARCH-2026 DEC-2024 FEB-2024 ANNOUNCEMENT* Drug Name Navtemadlin AJ1-11095 Rovadicitinib Elritercept Pelabresib MDS and MF Myelofibrosis Lead Indication / Myelofibrosis Myelofibrosis
Slide 11: BRIDGE-MF: Study Design
BRIDGE-MF: STUDY DESIGN Study designed to strengthen confidence in both efficacy and disease-modifying relevance Trial Design amsulostat Timeline of Activities rsonal use only Main Cohort A 200 mg BID + • Patients with MF on ruxolitinib for min 3 months Preparation Phase ruxolitinib BID • Current in
Slide 12: SNT-4728 for Neuroinflammation
SNT-4728: BRIEF HISTORY SNT-4728 FOR NEUROINFLAMMATION Safe and efficacious, small molecule enzyme inhibitor that crosses the rsonal use only blood brain barrier A novel approach • Syntara discovered and wholly • Strong preclinical and clinical owned asset data support the role of SSAO • Drug extens
Slide 13: iRBD and Parkinson's
iRBD AND PARKINSON’S Using a sleep disorder to target Parkinson’s. KEY FACTS Early intervention to demonstrate neuroprotection – rather than late treatment when most neurons have already been lost (for example in PD) – is where disease-modifying, rsonal use only • Patients with isolated REM sleep be
Slide 14: Reduction in Inflammation
REDUCTION IN Binding Potential (BPND) P-value INFLAMMATION Putamen Mean at Mean at Mean change (Paired t- test) baseline 12 weeks Statistically significant rsonal use only Right 0.002918 -0.012073 -0.016 (0.033) 0.0145 reduction in brain inflammation observed unilaterally in the Left -0.001209 0.001
Slide 15: Clinical Measures
CLINICAL MEASURES MDS-UPDRS Part III Total Score 10 SNT-4728, n=30 Signficant difference between rsonal use only Placebo, n=11 SNT-4728 and placebo in motor p=0.021 signs Mean Change, 95% CI p=0.183 5 MDS-UPDRS • Small decrease over time (even after treatment cessation) in the Part III total score w
Slide 16: Skin Scarring
SKIN SCARRING Leverage expertise in LOX inhibition Standard of Care: Fragmented, Ineffective and Outdated • Silicone sheeting (none to very limited effect) • Skin Scarring is a Global Disease • Steroid injections (temporary; high relapse) rsonal use only • Laser therapy (expensive; outcome operator
Slide 17: Clinical Proof of Concept Already Achieved
CLINICAL PROOF OF CONCEPT ALREADY ACHIEVED Placebo controlled study with first generation topical pan LOX inhibitor significantly de risks program SOLARIA2 Findings* rsonal use only “We now understand the biology well enough to target stiffness directly rather than just calming inflammation around i
Slide 18: Innovative Trial Design to Evaluate Commercial Viability
INNOVATIVE TRIAL DESIGN TO EVALUATE COMMERCIAL VIABILITY Placebo controlled scar remodeling study with multiple efficacy readouts in H2 2026 rsonal use only Healthy Volunteer Phase 1a Single Ascending Dose Trial design optimised for Dose-dependent target engagement confirmed inclusion criteria and
Slide 19: The Year Ahead - Poised to Deliver Near Term Value
THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 ANTICIPATED NEWS FLOW HEALTHY H2 2026 H1 2027 PATIENTS PARTICIPANTS rsonal use only FDA approved development plan Myelofibrosis Trial Progression and partner engagement Interim safety and High Risk MDS
Slide 20: Gary Phillips, Chief Executive Officer
rsonal use only Gary Phillips Chief Executive Officer gary.phillips@syntaratx.com.au Alison Findlay Head Business Development & Licensing alison.findlay@syntaratx.com.au http://syntaratx.com.au